IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): FINAL 24-MONTH RESULTS FROM THE PHASE III APPLAUSE-IgAN TRIAL

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

Abstract Title *

IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): FINAL 24-MONTH RESULTS FROM THE PHASE III APPLAUSE-IgAN TRIAL

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Vlado Perkovic vlado.perkovic@unsw.edu.au University of New South Wales Provost Office Sydney Australia *

Co-author 2

Naoki Kashihara kashinao@med.kawasaki-m.ac.jp Kawasaki Medical School Department of Nephrology and Hypertension Okayama Japan -

Co-author 3

Bart Maes bart.maes@azdelta.be AZ Delta Department of Nephrology Roeselare Belgium -

Co-author 4

Dana V Rizk drizk@uabmc.edu University of Alabama at Birmingham Nephrology Division, Department of Medicine Birmingham United States -

Co-author 5

Brad Rovin brad.rovin@osumc.edu The Ohio State University Wexner Medical Center Nephrology Division, Department of Medicine Columbus United States -

Co-author 6

Hernán Trimarchi htrimarchi@hotmail.com Hospital Británico de Buenos Aires Nephrology Service and Kidney Transplant Unit Buenos Aires Argentina -

Co-author 7

Hong Zhang hongzh@bjmu.edu.cn Peking University First Hospital Renal Division Beijing China -

Co-author 8

Frank Eitner frank.eitner@novartis.com Novartis Pharma AG Clinical Development Basel Switzerland -

Co-author 9

Nicolas Guerard nicolas.guerard@novartis.com Novartis Pharma AG Clinical Development Basel Switzerland -

Co-author 10

Dmytro Butylin dmytro.butylin@novartis.com Novartis Pharma AG Clinical Development Basel Switzerland -

Co-author 11

Luca Monaco luca-1.monaco@novartis.com Novartis Pharma AG Clinical Development Basel Switzerland -

Co-author 12

Annabel Magirr annabel.magirr@novartis.com Novartis Pharma AG Clinical Development Basel Switzerland -

Co-author 13

Ronny Renfurm ronny.renfurm@novartis.com Novartis Pharma AG Clinical Development Basel Switzerland -

Co-author 14

Thomas Hach thomas.hach@novartis.com Novartis Pharma AG Clinical Development Basel Switzerland -

Co-author 15

Jonathan Barratt jb81@leicester.ac.uk University of Leicester The Mayer IgA Nephropathy Laboratories Leicester United Kingdom - Leicester General Hospital The John Walls Renal Unit Leicester United Kingdom